Use access key #2 to skip to page content.
$12.30 -1.38 (-10.09%)
10/10/2008 4:00 PM

Amylin Pharmaceuticals, Inc. (AMLN)

CAPS Rating:
**

A biopharmaceutical company committed to improving the lives of people with diabetes, obesity and other diseases through the discovery, development and commercialization of innovative medicines.

View All Commentary (AMLN)

Recs

0

Avatar YancyG (< 20) Submitted: 12/19/06 5:31 PM : Underperform Start Price: $38.33 AMLN Score: 30.10

Byetta is a great drug. However with oral forms of similar drugs entering the market (eg Januvia) it will be difficult to retain market share with an injection.

Report this Post Replies: 0 | Reply

Featured Broker Partners